Recently, Hemlimbra® (emicizumab-kxwh), a humanized bispecific monoclonal antibody that restores FVIII function by bridging FIXa and FXa, has been approved by FDA for hemophilia A without FVIII inhibitors (Oldenburg et al., 2017; Scott and Kim, 2018). This evidence concerns the gene F8 and hemophilia A.